LSE:AZNPharmaceuticals
AstraZeneca (LSE:AZN) Stock Still Looks Like A Bargain Today
AstraZeneca has delivered a 59.1% gain over the past 5 years, yet the broader valuation checks still flag the stock as pricing in less optimism than many peers. With a recent pullback leaving the share price lower year to date, investors are weighing a softer near term run against signals that the market may be underpaying for the long term pipeline.
The 59.1% return over 5 years points to solid long haul wealth creation, even though shorter term performance has been far more muted.
Progress...